QP-Prostate®
AI assisted automation
for prostate MRIanalysis reading

CE Mark (MDR), 510(k) cleared by FDA,and UKCA mark-cleared.

QP-Prostate® | AI automation for assisted prostate MRI analysis

Discover QP-Prostate®
Prostate cancer ranks as the second most prevalent cancer

Introducing QP-Prostate, an AI-powered solution designed toin men, posing a significant public health concern. While MRI

streamline radiologists’ workflows. By automatically evaluatingscans are vital for early detection, the increased demand forimage quality, segmenting the prostate gland, and identifyingscans has outpaced the growth of radiology experts. This has

suspicious lesions*, QP-Prostate empowers radiologists toresulted in diagnostic delays and inconsistent interpretations,deliver quicker and more accurate assessments, ultimately

with only a minority of the medical community adhering toenhancing patient care.

PI-RADS v2.1 guidelines.

Introducing a suite of enhanced
diagnostic capabilities
1. Automated quality assessment

4. Quantitative diffusion and perfusion data

QP-Prostate automatically verifies MRI acquisition protocol
according to PI-RADS v2.1 guidelines, ensuring that radiologists
work with high-quality MRI examinations from the start.

QP-Prostate provides partially registered b 1400 DWI and ADC
image series, offering rich quantitative diffusion information.
This dataset empowers radiologists to analyze potentiallycancerous lesions with confidence.

2. Precision in segmentation
Our software segments the prostate gland with market-leading
accuracy (88%)1. It segments three key subregions (Peripheral,Transitional+Central zones, and Seminal Vesicles), includes
PI-RADS v2.1 regions, and computes prostate volume, facilitating
PSA density calculations and fusion biopsy planning.

5. Flawless PACS integration
Ensure consistent and seamless incorporation of all outputs
from QP-Prostate into your hospital’s PACS with no disruptions
to radiologists’ workflow.

3. AI-based automated lesion detection*
Our AI algorithm, trained with pathology data, is designed to detectsignificant prostate cancer lesions efficiently using biparametric
input (T2W and DWI), with plans to outperform competitors inaccuracy and speed. These AI algorithms are intended to elevatediagnostic accuracy with automated detection of biopsy-proven,clinically significant prostate cancer lesions.

*Lesion detection functionality is CE (MDR) and UKCA mark-cleared.
In the US is under clinical investigation and not available for sale.
WWW.QUIBIM.COM

3D model of prostate segmented from T2-weighted MRI

Changing thenarrative in prostate
diagnostics
1

Jimenez-Pastor A, et al. Eur Radiol. 2023;33(7):5087-5096.

2

Sánchez Iglesias Á, et al. Cancers (Basel). 2023;15(16):4163.

Experience confident, intelligent, and reliable prostate MRIinterpretation with QP-Prostate – your trusted solution providing
comprehensive insights and precise assessments for better patientcare and outcomes.
The product will be enhanced with predictive capabilities inupcoming versions, which are currently undergoing clinical studies
for imaging-based prediction of biochemical relapse. Recent studies
show that combining MRI with clinical data predicts a 10-year
biochemical recurrence with an area under the curve (AUC) of 0.84
to 0.872.

Clinical cases using QP-Prostate®
CASE 1

CASE 2

Patient history

Patient history

66 years old male, with elevated history of prostate
specific antigen (PSA).

Abnormal prostate exam nodule superior half of right prostate;firm. PSA of 31.3 ng/ml.

QP-Prostate Results

QP-Prostate Results

Summary

Summary

Seminal Vesicles

Base*clinically significant prostate cancerMid

Biopsy csPCa*

Biopsy csPCa

QP-Prostate

QP-Prostate

Original radiologist

Original radiologist

MidQP-Prostate® | AI automation for assisted prostate MRI analysis

CASE 3

CASE 4

Patient history

Patient history

61 years old man with elevated PSA, benign prostatic
hyperplasia with lower urinary tract symptoms;
PSA of 8.63 ng/mL.

62 year old male with history of low-grade prostate cancer
diagnosed with biopsy. Most recent PSA of 13.34 ng/mL
increased compared to prior which measures 9.99 ng/mL.

QP-Prostate Results

QP-Prostate Results

Summary

Summary
Biopsy csPCa

Biopsy csPCa

QP-Prostate

QP-Prostate

Original radiologist

Original radiologist
Seminal Vesicles
Vesículasseminales

BaseMid

Apex

Mid

Urethra

Apex

UrethraContact us: sales@quibim.com
US: +1 201-290-6110 / EU: +34 961 243 225

WWW.QUIBIM.COM© Quibim S.L. | All rights reserved | 24. V2. QPPR.ENGDPRHIPAA